Brought to you by 
Shire to buy BioChem for $4bn in stock
17 Jan 2001
Executive Summary
Shire Pharmaceuticals is buying Canadian biotech BioChem Pharma in an all-stock deal that values BioChem at $4bn. Each BioChem share will be exchanged for Shire shares currently valued at $37 each, a premium of (pr)39%, and there are collar provisions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire to buy BioChem for $4bn in stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice